Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × HER2 peptide (369-377) × Clear all
NCT02297698 2023-12-12

HER3+

Cancer Insight, LLC

Phase 2 Completed
100 enrolled 11 charts
Breast

Breast Neoplasms

NCT02636582 2023-12-05

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
43 enrolled 10 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01570036 2020-12-02

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Cancer Insight, LLC

Phase 2 Completed
275 enrolled 23 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡